Society of Family Planning Research Fund Grant Announcement: Medical Abortion Regimen in the Later First Trimester
Gynuity Health Projects received a grant from the Society of Family Planning Research Fund to assess a mifepristone and two-misoprostol-dose medical abortion regimen in the later first trimester (71 to 84 days).
For years now, Gynuity Health Projects has been strengthening the evidence base and making the case for incrementally expanding the gestational ages at which medical abortion is used in the first trimester. Our recent findings from a retrospective chart review demonstrate the great promise of mifepristone followed by two doses of 800 mcg of misoprostol in the 10th and 11th weeks of pregnancy to reduce the frequency of continuing pregnancies and improve success with the usual regimen of mifepristone and one misoprostol dose used earlier in the first trimester. This follow-on and more-rigorous prospective, multi-center, open-label study in abortion seekers with pregnancies in the 11th and 12th weeks (71-84 days) will evaluate efficacy, experiences with side effects and expulsion, as well as acceptability among both study participants and study providers. We will also pilot counseling messages and materials.
Having a reliable regimen for mifepristone-misoprostol medical abortion at 11-12 weeks would greatly expand access to safe abortion care, particularly at clinics that only offer medical abortion and not aspiration. Favorable outcomes could also provide people around the world who choose self-managed abortion greater reassurance about the efficacy of the regimen.
The study is being led by Ilana Dzuba.